Omeros Corp. Stock
Price
Target price
€3.61
€3.61
1.410%
0.05
1.410%
€31.82
09.09.25 / Frankfurt
WKN: A0NBFF / Symbol: OMER / Name: Omeros / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Omeros Corp. Stock
Omeros Corp. gained 1.410% today.
Omeros Corp. is currently one of the favorites of our community with 12 Buy predictions and no Sell predictions.
Based on the current price of 3.61 € the target price of 31 € shows a potential of 759.68% for Omeros Corp. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Omeros Corp. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Non-cyclic/Cyclic" there were negative voices in the community.
Pros and Cons of Omeros Corp. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Omeros Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Omeros Corp. | 1.410% | -3.317% | 4.465% | 10.986% | -68.108% | -32.472% | -61.204% |
| Krystal Biotech | 0.790% | -5.896% | 1.048% | -29.222% | -20.828% | 68.531% | - |
| Ardelyx Inc. | -0.320% | 1.890% | 25.179% | 8.682% | 12.951% | 335.066% | 13.868% |
| Evolus Inc | -2.420% | -1.575% | 25.000% | -51.172% | -40.476% | -38.119% | 94.704% |
Comments
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Show more
Ratings data for OMER provided by MarketBeat
Omeros Corporation (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Show more
Ratings data for OMER provided by MarketBeat
Omeros Corporation (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Show more
Ratings data for OMER provided by MarketBeat
News
Omeros Posts 2,652 Percent Sales Jump
Omeros (NASDAQ:OMER), a biopharmaceutical company focused on developing treatments for rare diseases and immune-related conditions, released its second quarter results on August 14, 2025. The
